Q2 2025 Earnings Call Transcript August 7, 2025 Operator: Good day, and thank you for standing by. Welcome to the Arcutis ...

Pacira BioSciences boasts a strong balance sheet with $495 million in cash and a new $300 million stock buyback authorization ...

Integrating waste foundry sand with SCMs like metakaolin and silica fume significantly boosts concrete strength and ...

Corvus Pharmaceuticals reported a net loss per share of $(0.10) for Q2 2025, a smaller loss than the analyst estimate of $(0.13). Research and development expenses rose sharply to $7.9 million, ...

Tauranga's on-demand public transport trial is being extended, with the regional council saying it needs more information ...

An expert discusses the transformative impact of CAR T-cell therapy in relapsed/refractory large B-cell lymphoma, ...

Key Points Revenue (GAAP) rose 30% to $98.0 million in the quarter, topping GAAP revenue estimates by $5.85 million. Earnings per share (GAAP) of $(0.20) missed GAAP EPS estimates due to higher R&D ...

Luye Pharma Group today announced that the first subject has been enrolled in a Phase 1 clinical trial in China for its LY03021, which was filed through China's Class 1 pathway for innovative drugs.

With impressive infotainment options, including large touchscreen displays and wireless smartphone integration, both the ...

Americans are drowning in subscriptions for services like Netflix, Disney, and Verizon. So, they're saving money by joining family plans with friends.